Last reviewed · How we verify
NCT03972228
Microdevice for Evaluating Drug Response in Site in Lung Lesions
EARLY_PHASE1 trial testing Microdevice loaded with 19 chemotherapeutic agents in Lung Tumor in 5 participants. Completed in 1 September 2021.
1 September 2021
Quick facts
| Lead sponsor | Oliver Jonas |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 1 October 2018 |
| Primary completion | 1 September 2021 |
| Estimated completion | 1 September 2021 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Microdevice loaded with 19 chemotherapeutic agents
Conditions studied
- Lung Tumor — all drugs for Lung Tumor →
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Oliver Jonas
Who can join
18 and older, any sex, with Lung Tumor or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study for placement of a tiny microdevice into lung tumors to more precisely predict tumor-specific drug sensitivity, and to help inform systemic therapeutic decisions. The microdevice will provide a novel technique for interrogating human lung tumor tissue in situ, and will uniquely facilitate assessment of response to multiple drugs simultaneously. This will not only increase the specificity of a particular participant's chosen systemic therapy, it will also augment the speed and efficiency with which investigators are able to make clinical decisions regarding choice of therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.
Cotler MJ, Ramadi KB, Hou X, Christodoulopoulos E, et al · · 2022 · cited 4× · PMID 35472731 · DOI 10.1016/j.tranon.2022.101427 -
Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a review.
Quinn TM, Bruce AM, Burt T, Dhaliwal K. · · 2024 · PMID 39210357 · DOI 10.1186/s12890-024-03193-5
Verify or expand the search:
- PubMed search for NCT03972228
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Tumor
Currently open trials in the same condition.
- NCT06322329 — RealMove (Lung): Assessing Tumour Motion With Dynamic MRI · NA · recruiting
- NCT04075305 — The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study · recruiting
Other Oliver Jonas trials
Trials by the same sponsor.
- NCT05700461 — Drug Screening Using Novel IMD in Renal Cell Carcinoma · Phase 1 · enrolling by invitation
- NCT04135807 — Implantable Microdevice In Primary Brain Tumors · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03972228 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oliver Jonas
- Last refreshed: 17 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03972228.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing